Utidelone before surgery for high-risk breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a chemotherapy drug called utidelone given before surgery to shrink high-risk or locally advanced breast cancer. It may help make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have been newly diagnosed with breast cancer (Stage II or III) and haven't had treatment yet.
- Your cancer is a type called HR+, HER2-, triple negative, or HER2+.
- You are in good general health (able to do daily activities without help, and your blood counts and organ function are near normal).
- You do not have serious heart problems, nerve damage, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two chemotherapy drugs (Utidelone and Cisplatin) given before surgery for breast cancer. It is for people with early-stage breast cancer that has not spread to other parts of the body, and aims to shrink the tumor to make surgery more effective.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
This trial tests if adding UTD2 to capecitabine works better than capecitabine alone for triple-negative breast cancer that didn't completely disappear after chemo. It's for patients who had surgery and are at risk of cancer coming back.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
This trial tests whether a customized treatment plan given before surgery can improve outcomes for women with early-stage HR-positive, HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.